相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- Shawn Patrick O'Brien, former CEO of Mayne Pharma, has been honored by Marquis Who's Who for over 40 years of expertise in pharmaceuticals and biotechnology. - During his 17-year tenure at AstraZeneca, O'Brien led the relaunch of Seroquel, growing revenue from $110 million to $5.6 billion and overseeing eight blockbuster brand launches. - O'Brien has held five CEO roles across companies including Cipher Pharmaceuticals, Altherx, Profectus BioSciences, and Solstice Neurosciences, and currently chairs SFA Therapeutics. - The recognition highlights a career spanning supply chain management, commercialization, and product development with a focus on women's health and dermatology at Mayne Pharma.
- Moberg Pharma reports that a subset of patients in their North American Phase 3 study of MOB-015 achieved clinical cure for nail fungus at a rate lower than anticipated. - Cipher Pharmaceuticals, which holds Canadian marketing rights to MOB-015, acknowledges the update from Moberg Pharma regarding the clinical trial results. - Cipher Pharmaceuticals emphasizes that the outcome of the MOB-015 trial does not currently impact the company's sales and earnings profile. - Cipher Pharmaceuticals remains focused on the integration of the Natroba™ business and other potential growth opportunities.
